Completed PHASE2 INTERVENTIONAL 1-arm NCT00649961

Melatonin As A Novel Neuroprotectant In Preterm Infants- Dosage Study (MIND)

Sponsor: British Medical Research Council

Updated 9 times since 2017 Last updated: Aug 6, 2019 Started: May 31, 2010 Primary completion: Feb 28, 2011 Completion: Feb 28, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00649961, this PHASE2 trial focuses on Brain Injury and Premature Birth and remains completed. Sponsored by British Medical Research Council, it has been updated 9 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Sep 2019 — Jan 2021 [monthly]

Completed PHASE2
May 2019 — Sep 2019 [monthly]

Completed PHASE2
Jun 2018 — May 2019 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

British Medical Research Council
Imperial College London

Data source: Imperial College London

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bolton, United Kingdom
• London, United Kingdom